FCE 28260 is an orally active 4-azacyclic 5alpha-reductase (5alphaR) inhibitor. FCE 28260 exhibits IC50 values for human 5alphaR type 1 and 5alphaR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC50 values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH)[1].
Molecular Weight:
488.58
CAS Number:
[155651-56-2]
Formula:
C28H35F3N2O2
Target:
5 alpha Reductase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
